Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Braze Inc (BRZE) vs Mesoblast Limited (MESO) Price & Performance

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Braze Inc vs Mesoblast Limited — how do they compare? Braze Inc trades at $28.27 (market cap $3.18B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Braze Inc is the larger of the two by market cap, and Braze Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

BRZEMESO
Market Cap
$3.18B$2.21B
Sector
TechnologyTechnology
52-Week High
$36.19$20.96
52-Week Low
$15.79$12.88
Enterprise Value
$2.87B$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Braze Inc

BRZE trades at $27.68, down 3.72% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is strong at 30% year-over-year, though the company remains unprofitable with a net margin of -15.51%. Recent news highlights insider selling and a 15% weekly rebound amid AI sector momentum.

The stock offers growth exposure with a consensus price target of $34.78, but risks include persistent losses, competitive pressures, and high valuation multiples. Analyst sentiment is overwhelmingly bullish, yet profitability challenges and insider sales warrant caution for investors seeking near-term returns.

Mesoblast Limited

MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.

MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.

Returns comparison

Trailing returns across standard periods

About Braze Inc

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.

Read more on BRZE

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO